Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of GS-6615 for prevention of ventricular arrhythmia in patients with ICD or CRT-D
NL-OMON42304Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of eleclazine in ventricular arrhythmia (VA) (3 arms), sponsored by Gilead Sciences. Primary endpoints: Overall occurrence of appropriate ICD interventions through Week 24, Time from first dose to death due to any cause and 1 more. Started Jul 2015; status: active, not recruiting.
02
Drugs
eleclazine
03
Conditions
ventricular arrhythmia (VA)
Beyond the preview
Go deeper on NL-OMON42304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42304.